SCHEMBL273451

SCHEMBL273451

C[C@@H](O)[C@H](N)C(=O)N[C@H](CCC(=O)O)C(N)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSC P53634 1/20 0.53
NOD1 Q9Y239 1/20 0.46
GABRP O00591 2/20 0.44
GABRD O14764 2/20 0.44
GABRA1 P14867 2/20 0.44
GABRB1 P18505 2/20 0.44
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44
GABRA5 P31644 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRA2 P47869 2/20 0.44
GABRB2 P47870 2/20 0.44
GABRA4 P48169 2/20 0.44
GABRE P78334 2/20 0.44
GABRA6 Q16445 2/20 0.44
GABRG1 Q8N1C3 2/20 0.44
GABRG3 Q99928 2/20 0.44
GABRQ Q9UN88 2/20 0.44
ERAP2 Q6P179 1/20 0.43
ERAP1 Q9NZ08 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27880528 1.00 CTSC (0.53) CTSCNOD1GABRPGABRDGABRA1
SCHEMBL31344439 1.00 CTSC (0.53) CTSCNOD1GABRPGABRDGABRA1
SCHEMBL10379813 0.89 NOD1 (0.47) CTSCNOD1GABRPGABRDGABRA1
SCHEMBL10804597 0.89 CTSC (0.58) CTSCNOD1GABRPGABRDGABRA1
SCHEMBL15011502 0.89 CTSC (0.58) CTSCNOD1GABRPGABRDGABRA1
SCHEMBL10804587 0.89 CTSC (0.58) CTSCNOD1GABRPGABRDGABRA1
SCHEMBL4217551 0.85 NOD1 (0.59) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL7927426 0.85 NOD1 (0.59) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL11103615 0.85 NOD1 (0.59) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL27892995 0.85 NOD1 (0.59) NOD1GABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0135376-B1 POLYOXYPROPYLENE-POLYOXYETHYLENE BLOCK POLYMER BASED ADJUVANTS AND VACCINES USING THEM SYNTEX (U.S.A.) INC. (US) 1990-11-07 EP claimed
US-20250345410-A1 VACCINATION IN NEWBORNS AND INFANTS CureVac SE (DE) 2025-11-13 US disclosed
WO-2023213393-A1 STAPHYLOCOCCAL PROTEIN VARIANTS AND TRUNCATES EVAXION BIOTECH A/S (DK) 2023-11-09 WO disclosed
US-11672856-B2 Vaccination in newborns and infants CureVac SE (DE) 2023-06-13 US disclosed
EP-4189686-A2 PROCESS FOR PREPARATION OF NEOPEPITOPE-CONTAINING VACCINE AGENTS Evaxion Biotech A/S (DK) 2023-06-07 EP disclosed
WO-2022032099-A9 NEISSERIAL SURFACE PROTEIN A (NSPA) VARIANTS AND METHODS OF USE THEREOF CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) 2022-09-15 WO disclosed
EP-4028763-A1 METHOD FOR IDENTIFYING T-CELL EPITOPES Evaxion Biotech A/S (DK) 2022-07-20 EP disclosed
WO-2022023521-A2 PROCESS FOR PREPARATION OF NEOPEPITOPE-CONTAINING VACCINE AGENTS EVAXION BIOTECH A/S (DK) 2022-02-03 WO disclosed
WO-2021048400-A1 METHOD FOR IDENTIFYING T-CELL EPITOPES EVAXION BIOTECH APS (DK) 2021-03-18 WO disclosed
WO-2021048381-A1 METHOD FOR IDENTIFYING STABLE MHC BINDING PEPTIDES USING MASS SPECTROMETRY EVAXION BIOTECH APS (DK) 2021-03-18 WO disclosed
EP-1234039-A2 85kDa NEISSERIAL ANTIGEN Chiron Spa (IT) 2002-08-28 EP disclosed
WO-2001038350-A2 85kDa NEISSERIAL ANTIGEN CHIRON SPA (IT) 2001-05-31 WO disclosed
EP-1042001-A1 USE OF MICROPARTICLES COMBINED WITH SUBMICRON OIL-IN-WATER EMULSIONS CHIRON CORPORATION (US) 2000-10-11 EP disclosed
EP-1006999-A2 USE OF SUBMICRON OIL-IN-WATER EMULSIONS WITH DNA VACCINES Chiron Corporation (US) 2000-06-14 EP disclosed
WO-1999030737-A1 USE OF MICROPARTICLES COMBINED WITH SUBMICRON OIL-IN-WATER EMULSIONS CHIRON CORPORATION (US) 1999-06-24 WO disclosed
WO-1999002132-A2 USE OF SUBMICRON OIL-IN-WATER EMULSIONS WITH DNA VACCINES CHIRON CORPORATION (US) 1999-01-21 WO disclosed
EP-0582672-A4 METHODS TO DETECT AND TREAT DISEASES CAUSED BY BACTERIAL ALLERGENS CALENOFF EMANUEL (US) 1994-06-29 EP disclosed
EP-0582672-A1 METHODS TO DETECT AND TREAT DISEASES CAUSED BY BACTERIAL ALLERGENS CALENOFF, Emanuel (US) 1994-02-16 EP disclosed
WO-1992019970-A1 METHODS TO DETECT AND TREAT DISEASES CAUSED BY BACTERIAL ALLERGENS CALENOFF EMANUEL (US) 1992-11-12 WO disclosed
EP-0315153-A2 Vaccine adjuvant SYNTEX (U.S.A.) INC. (US) 1989-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250345410-A1 VACCINATION IN NEWBORNS AND INFANTS HLA-DRB1, TLR3, TLR9 CTSC 2401/4885NOD1 1717/4885GABRP 3806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.